# CONMED Corp: overview

CNMD · NYSE · CIK 816956 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cnmd.md) · [Financials](/companies/cnmd/financials.md) · [Filings](/companies/cnmd/filings.md) · [Insiders](/companies/cnmd/insiders.md)

Latest reported revenue: [$343.5m](/filings/0000816956-26-000102.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000816956-26-000102).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [332](/filings/0000816956-25-000028.md) | [317](/filings/0000816956-25-000056.md) | [346 d](/filings/0000816956-26-000009.md) | [321](/filings/0000816956-25-000011.md) | [342](/filings/0000816956-26-000102.md) | [338](/filings/0000816956-25-000056.md) | [373 d](/filings/0000816956-26-000009.md) | [343](/filings/0000816956-26-000102.md) |
| Gross margin | % | [55.3%](/filings/0000816956-25-000028.md) | [56.5%](/filings/0000816956-25-000056.md) | [57.3% d](/filings/0000816956-26-000009.md) | [55.3%](/filings/0000816956-25-000011.md) | [55.0%](/filings/0000816956-26-000102.md) | [49.2%](/filings/0000816956-25-000056.md) | [58.5% d](/filings/0000816956-26-000009.md) | [57.5%](/filings/0000816956-26-000102.md) |
| Operating margin | % | [14.2%](/filings/0000816956-25-000028.md) | [20.7%](/filings/0000816956-25-000056.md) | [15.2% d](/filings/0000816956-26-000009.md) | [5.0%](/filings/0000816956-25-000011.md) | [11.1%](/filings/0000816956-26-000102.md) | [3.5%](/filings/0000816956-25-000056.md) | [9.8% d](/filings/0000816956-26-000009.md) | [10.6%](/filings/0000816956-26-000102.md) |
| Net margin | % | [9.0%](/filings/0000816956-25-000028.md) | [15.5%](/filings/0000816956-25-000056.md) | [9.8% d](/filings/0000816956-26-000009.md) | [1.9%](/filings/0000816956-25-000011.md) | [6.3%](/filings/0000816956-26-000102.md) | [0.8%](/filings/0000816956-25-000056.md) | [4.5% d](/filings/0000816956-26-000009.md) | [6.7%](/filings/0000816956-26-000102.md) |
| Diluted EPS | $ per share | [0.96](/filings/0000816956-25-000028.md) | [1.57](/filings/0000816956-25-000056.md) | not reported | [0.19](/filings/0000816956-25-000011.md) | [0.69](/filings/0000816956-26-000102.md) | [0.09](/filings/0000816956-25-000056.md) | not reported | [0.77](/filings/0000816956-26-000102.md) |
| Free cash flow | $m | [39.7 d](/filings/0000816956-25-000028.md) | [47.8 d](/filings/0000816956-25-000056.md) | [39.3 d](/filings/0000816956-26-000009.md) | [37.8](/filings/0000816956-25-000011.md) | [23.4 d](/filings/0000816956-26-000102.md) | [48.5 d](/filings/0000816956-25-000056.md) | [41.2 d](/filings/0000816956-26-000009.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,011](/filings/0000816956-24-000003.md) | [1,045](/filings/0000816956-25-000004.md) | [1,245](/filings/0000816956-26-000009.md) | [1,307](/filings/0000816956-26-000009.md) | [1,375](/filings/0000816956-26-000009.md) |
| Gross margin | % | [56.2%](/filings/0000816956-24-000003.md) | [54.6%](/filings/0000816956-25-000004.md) | [54.3%](/filings/0000816956-26-000009.md) | [56.1%](/filings/0000816956-26-000009.md) | [54.6%](/filings/0000816956-26-000009.md) |
| Operating margin | % | [10.9%](/filings/0000816956-24-000003.md) | [6.7%](/filings/0000816956-25-000004.md) | [9.7%](/filings/0000816956-26-000009.md) | [15.3%](/filings/0000816956-26-000009.md) | [7.5%](/filings/0000816956-26-000009.md) |
| Net margin | % | [6.2%](/filings/0000816956-24-000003.md) | [(7.7%)](/filings/0000816956-25-000004.md) | [5.2%](/filings/0000816956-26-000009.md) | [10.1%](/filings/0000816956-26-000009.md) | [3.4%](/filings/0000816956-26-000009.md) |
| Diluted EPS | $ per share | [1.94](/filings/0000816956-24-000003.md) | [(2.68)](/filings/0000816956-25-000004.md) | [2.04](/filings/0000816956-26-000009.md) | [4.25](/filings/0000816956-26-000009.md) | [1.51](/filings/0000816956-26-000009.md) |
| Free cash flow | $m | [96.9](/filings/0000816956-24-000003.md) | [11.6](/filings/0000816956-25-000004.md) | [106](/filings/0000816956-26-000009.md) | [154](/filings/0000816956-26-000009.md) | [151](/filings/0000816956-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cnmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $157.8m | 4,820,739 |  | Reduced −4,434 |
| [EARNEST PARTNERS LLC](/funds/1102578.md) | 2026-06-30 | $82.0m | 2,505,295 |  | Reduced −64,358 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $71.6m | 2,188,761 |  | Added +112,344 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $51.7m | 1,579,917 |  | Reduced −61,849 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $46.4m | 1,417,468 |  | Added +33,450 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $44.4m | 1,355,728 |  | Reduced −28,314 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $43.9m | 1,341,409 |  | Reduced −61,211 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $43.1m | 1,317,370 |  | Reduced −75,550 |
| [SEI INVESTMENTS CO](/funds/350894.md) | 2026-06-30 | $32.3m | 988,151 |  | Reduced −16,564 |
| [Invenomic Capital Management LP](/funds/1769456.md) | 2026-06-30 | $27.6m | 842,162 |  | Reduced −92,439 |

## Recent filings

[All 1,640 filings](/companies/cnmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-29 | 16:13 ET | [10-Q](/filings/0000816956-26-000102.md) | Quarterly report, period 2026-06-30 | 0000816956-26-000102 |
| 2026-07-29 | 16:10 ET | [8-K](/filings/0000816956-26-000101.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000816956-26-000101 |
| 2026-06-17 | 16:49 ET | [8-K](/filings/0002077096-26-000203.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0002077096-26-000203 |
| 2026-06-04 | 07:30 ET | [8-K](/filings/0001174947-26-000639.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001174947-26-000639 |
| 2026-06-01 | 08:31 ET | [8-K](/filings/0002077096-26-000190.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0002077096-26-000190 |
| 2026-05-20 | 08:30 ET | [8-K](/filings/0000816956-26-000057.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000816956-26-000057 |
| 2026-04-30 | 09:52 ET | [10-Q](/filings/0000816956-26-000053.md) | Quarterly report, period 2026-03-31 | 0000816956-26-000053 |
| 2026-04-29 | 16:18 ET | [8-K](/filings/0000816956-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000816956-26-000051 |
| 2026-04-07 | 08:23 ET | [DEF 14A](/filings/0000816956-26-000047.md) | Proxy statement, period 2026-05-18 | 0000816956-26-000047 |
| 2026-03-13 | 16:01 ET | [8-K](/filings/0001213900-26-027658.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-027658 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000816956-26-000009.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6121fa0e-918d-426f-bf66-3849453a1401)

## About the filer

- CIK: 816956
- Tickers: CNMD
- Exchange: NYSE
- SIC code: 3845 Electromedical & Electrotherapeutic Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.